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Abstract
Poly(lactic-co-glycolic acid) nanocapsules containing amphiphilic biosurfactant sophorolipids were formulated using a
dispersion-based procedure. Di-block copolymers were used to vary peripheral poly(ethylene glycol) density, and variation in
the oil core was used to achieve efficient encapsulation of the sophorolipid payload. Particulate size, zeta potential, encapsulation
efficiency, release and stability were characterised. A glyceryl monocaprate core composition had the lowest particulate size,
maximum encapsulation efficiency and optimum shelf-life stability compared to other formulations. This core composition was
used to deliver sophorolipid to both in vitro and in vivo model tumour cell lines (CT26 murine colon carcinoma) and the effect of
peripheral hydrophilicity was evaluated. Formulations with 10% poly(ethylene glycol) density achieved more than 80% reduc-
tion in cancer cell viability after 72 h and enhanced cellular uptake in CT26 cells. These formulations exhibited higher tumour
accumulation and a longer blood circulation profile when compared to the non-poly(ethylene glycol)-containing nanocapsules.
Animals treated with sophorolipid-loaded nanocapsules showed a tumour growth inhibition of 57% when compared to controls.
An assessment of tumour mass within the same study cohort showed the biggest reduction when compared control and free drug-
treated cohorts. This study shows that hydrophilic poly(lactic-co-glycolic acid) nanocapsules loaded with sophorolipids can
address the poor intracellular delivery associated with these biosurfactants and is a promising approach for the treatment of colon
neoplasia.
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Introduction
Natural surfactants are classified according to their chemical
composition and source of origin (plant or microorganism)
[1]. Specific types derived frommicroorganism-based sources
are characterised further on the basis of molecular weight and
segregated into two separate classes, known as the
biosurfactants and the bioemulsifiers. The former possess ex-
cellent surface activity and are able to lower interfacial ten-
s ions between immiscible phases. However, the
bioemulsifiers are less effective at doing this, yet still act as
effective emulsifiers [2]. These useful properties give rise to a
broad range of applications spanning the pharmaceutical and
medicinal fields. These include inhibition of bacterial growth,
stimulation of immune response, enzyme stimulation, tumour
growth inhibition, cell lysis (haemolysis), food digestion and
antifungal activity [3].
Biosurfactants with a carbohydrate moiety (glycolipid)
have therapeutic potential in the management of disease.
Four main types are recognised. These are the (i)
sophorolipids (SL), (ii) trehalolipids, (iii) mannosylerythritol
lipids and (iv) rhamnolipids [4]. The SL biosurfactants are of
particular interest and produced by yeasts, such as Candida
floricola, Candida apicola, Candida bastistaeic and
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Starmerella bombicola [5]. SL are assembled using a hydro-
philic carbohydrate head, composed of a disaccharide
(sophorose), linked to a hydrophobic fatty acid tail [6].
Recently, the anticancer activity and tumour growth inhibition
of SL in different types of cancer cell lines have been reported
[7, 8]. Activity has been demonstrated against a broad range of
tumour-derived cell lines, including liver (H7402 cells), lung
(A549 cells) and leukaemia (K562 cells) [5]. Further reports
also show activity against breast (MDA-MB231 cells) [9] and
colon (HT29, HT115, HCT116 cells) [10]. A detailed biomo-
lecular study performed on HeLa cells demonstrates that lac-
tonic sophorolipids induce features associated with apoptosis,
along with expression of pro-apoptotic biomarkers, such as
caspase-3 and caspase-12 and activation through endoplasmic
reticulum signalling pathways with cell-cycle blocking at both
G0 and G2 phases [11].
Although preliminary investigations demonstrate promise,
the translational applications of SL for the treatment of disease
have been hindered by a number of factors, such as high
production cost, limited purification, poor aqueous solubility
and an overall lack of understanding of interactions with cells
[1]. Therefore, an aim of this present study was to evaluate a
nanoparticulate-based delivery strategy to enhance adminis-
tration of SL and address the poor cellular bioavailability.
Given that colloidal carriers target specified locations and
overcome issues associated with poor drug solubility [12,
13], the design approach chosen was based on polymeric
nanocapsules (NCs). They exhibit a distinctive core-shell
structure in which active water-insoluble drug substances are
confined in an oil core surrounded by a polymeric membrane
[14]. In addition, encapsulation enables sustained and con-
trolled release kinetics in both in vitro and in vivo systems
[15–17]. These beneficial attributes may overcome the prob-
lems associated with delivery of SL due to its poor water
solubility.
A second aim of the study was to evaluate the effect of
polymer hydrophilicity. Previous studies have shown that
NC formulated from PEGylated PLGA polymers have im-
proved the anticancer effects of lipophilic drugs, such as
curcumin, used in the investigational treatment of colon neo-
plasia [12, 18]. PEGylated PLGA was used as it has been
shown to be an effective encapsulating matrix with reported
enhancement of the antitumour activity of various anticancer
molecules, such as small molecular chemotherapeutics or
larger biomolecular anticancer peptides [19–21].
Furthermore, colloidal PEGylated PLGA formulations pos-
sess (i) high drug loading of both hydrophilic and hydropho-
bic drugs, (ii) controlled release profiles, (iii) good in vitro
stability and (iv) novel bio-distribution arising from passive
targeting [22, 23]. The third aim was to evaluate cellular up-
take, localisation and cytotoxicity of SL-loaded NC using a
colon cancer cell and an in vivo murine model. To the best of
our knowledge, this is the first study to have demonstrated the
antitumour activity of SL-loaded NC against CT-26 colon
cancer cells (in vitro) and in in vivo murine model.
Materials and methods
Materials and reagents
PEG-PLGA diblock copolymers (Resomer® RGP d 5055
(5% PEG of MW 5 kDa) and Resomer® RGP d 50105
(10% PEG of MW 5 kDa)) were purchased from Boehringer
Ingelheim Ltd. (Ingelheim, Germany). PLGA with a 50:50
lactic:glycolic ratio (Resomer® RG 503H, MW 34 kDa)
was purchased from Sigma-Aldrich (St. Louis, USA).
Sophorolipid (1′,4″-Sophorolactone 6′,6″-diacetate; from
y e a s t ) , c o um a r i n 6 ( 3 - ( 2 - B e n z o t h i a z o l y l ) -
7-(diethylamino)coumarin, 3-(2-Benzothiazolyl)-N,N
diethylumbelliferylamine), DiR (1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindotricarbocyanine iodide), DAPI (4′,6-
diamidino-2-phenylindole), dialysis tubing (MWCO
2000 Da), SP-Sephadex C-25 resin, castor oil, palm oil,
Tween® 80, acetone and absolute ethanol (ultra-pure grades)
were obtained from Sigma-Aldrich (St. Louis, USA).
Glyceryl monocaprate (Capmul®MCMC10) was a generous
gift from ABITEC Corporation, USA. RPMI-1640 and
DMEM media, trypsin/EDTA, phosphate buffered saline
(PBS), fetal bovine serum (FBS) and penicillin/streptomycin
were obtained from Gibco, Invitrogen, UK. Isoflurane
(IsoFlo®) was purchased from Abbott Laboratories Ltd.
(UK).
Solubility of SL in the oil phase
The solubility of SL in three different oils used for NC prep-
aration (castor oil, palm oil and glyceryl monocaprate) was
determined using a simple saturation method [12]. An excess
of SL (5 mg) was placed in glass vials containing a sample of
the test oil (1.0 ml) and agitated at 100 rpm for 48 h at 37 °C.
After centrifugation, 100μl of supernatant was withdrawn and
mixed with an acetone/ethanol mixture (1:1 v/v). The concen-
tration of SL dissolved in the organic solvent was determined
using a calibrated UV spectrophotometric method, measuring
absorbance at 207 nm (Model UV-1601 PC; Shimadzu,
Kyoto, Japan) [24].
Preparation of SL-loaded polymeric NC
SL-loaded NCs were prepared using a modif ied
nanoprecipitation method [25]. Polymer (50 mg), SL (5 mg),
soybean lecithin (25 mg) and oil phase (300 μl) were dis-
solved in 5 ml of an acetone/ethanol (1:1 v/v) mixture. This
non-aqueous phase was added dropwise into an aqueous
phase (10 ml) containing 0.2% w/w of Tween® 80. The final
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mixture was stirred for 30 min to facilitate solvent diffusion
and formation of NC. Organic solvent was eliminated using
evaporation under reduced pressure and rotation. Blank NC
(non-SL-loaded) were prepared using identical conditions but
without adding SL to the oil phase. The SL-loaded NC sus-
pension was purified by passing down a PD10 desalting col-
umn (GE Healthcare) installed on a purifier system with an
eluent composition of 50 mM potassium phosphate and
100 mM NaCl (pH 7) and a flow rate of 1.0 ml min−1 to
remove non-entrapped drug.
Fluorescent SL-loadedNCswere prepared by adding either
coumarin 6 (100 μg) or DiR (150 μg) to the non-aqueous
phase. Coumarin 6 was chosen for qualitative cellular uptake
analysis, and DiR labelling was used an instrument-specific
dye to provide optimum in vivo biodistribution imaging data.
Process variables, such as the polymer type and composition
of the oil core, were modified, as shown in Table 1, along with
the identifying code for each SL-loaded NC formulation.
Physicochemical characterisation of SL-loaded NC
Particle size, size distribution and poly dispersity index (PDI)
of SL-loaded NCs were determined using dynamic light scat-
tering at 90° (Zetasizer 5000, Malvern Instruments, Malvern,
UK). A liquid aliquot from the SL-loaded NC colloidal sus-
pension was diluted in ultrapure water and an average of three
measurements was recorded. Zeta potential (ζ-potential) of
SL-loaded NC was determined using laser Doppler electro-
phoresis applied to an aliquot of colloidal suspension, diluted
in aqueous 0.001 M KCl to adjust for conductivity (Zetasizer
5000, Malvern Instruments, Malvern, UK). Morphology was
examined using transmission electron microscopy (TEM)
(JOEL JEM 2000 EX200). A sample of NC suspension was
placed on a Formvar-coated grid operating at an accelerating
voltage of 80 kV. Fluorescent SL-loaded NCs were evaluated
using similar methods for particle size, polydispersity index
and zeta potential.
In vitro stability
Samples of SL-loaded NC suspensions were sealed in glass
vials and stored in the dark under refrigeration (4 °C). Stability
was evaluated every 10 days by visual inspection of physical
properties (colour, turbidity and opacity) and by determination
of size, PDI and zeta-potent ia l , as descr ibed in
“Physicochemical characterisation of SL-loaded NC” section.
Each sample was tested three times and the measurements
were presented as an average ± SD.
Determination of SL encapsulation efficiency (%EE)
The percentage SL encapsulation efficiency (%EE) in SL-loaded
NC was determined by an indirect method of analysis. The
amount of non-encapsulated SL in fractions following column
purification of a NC suspension was determined by HPLC
(Shimadzu, Tokyo, Japan). A reversed-phase column
(Phenomenex-Luna® C18–5 column mm, 5 μm) and a mobile
phase, at a flow rate of 1.0 ml min−1, comprising a linear gradient
of acetonitrile andwater over a run time of 40min,were used [24].
In vitro release profile
A liquid sample of SL-loaded NC formulation containing a
predetermined amount of SL was placed into a 10-kDa dialy-
sis bag. The dialysis membrane was dialysed against a receiv-
er medium of 50 ml PBS containing Tween® 80 (1% w/v) at
pH 7.4. The release was studied at 37 °C at 100 rpm. At
predetermined time interval points, 1.0 ml sample was taken
and replaced by an equivalent amount of fresh medium, there-
by maintaining sink conditions. Drug concentration was
assessed by HPLC, as previously described.
Seeding of CT26 and CCD-841-CoN cells
CT26 murine colon carcinoma (CT26) cells were grown in
100 cm2 canted-neck tissue culture flasks. Cells were cultured
in complete RPMI media supplemented with FBS (10% v/v),
L-glutamine (2 mmol l−1), penicillin (100 U ml−1) and strep-
tomycin (100 μg ml−1). CCD-841-CoN, normal colonic epi-
thelium cells, were maintained in complete DMEM media
supplemented with 10% fetal bovine serum. Cells were pas-
saged every 3 days at 80% confluence. All cultures were in-
cubated at 5% CO2 and 37 °C.
CT26 cells were harvested when the cells were 90% con-
fluent. The cell suspension was centrifuged at 1500g (4 °C)
for 5 min and the pellet resuspended in RPMI complete
growth medium. A cell count was performed on a sample of
cell suspension (10 μl) using a haemocytometer. CCD-841-
CoN cells were seeded using similar conditions, with DMEM
complete growth medium being used instead of RPMI
medium.
Table 1 Formulation identifiers for polymer type and oil core
Formulation identifier Polymer type Oil core
F1 PLGA Castor oil
F2 PLGA Palm oil
F3 PLGA Glyceryl monocaprate
F4 5% PEG-PLGA Castor oil
F5 5% PEG-PLGA Palm oil
F6 5% PEG-PLGA Glyceryl monocaprate
F7 10% PEG-PLGA Castor oil
F8 10% PEG-PLGA Palm oil
F9 10% PEG-PLGA Glyceryl monocaprate
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Fluorescence analysis of SL-loaded NC cellular uptake
Cellular uptake of coumarin 6-tagged SL-loaded NC (F3, F6
and F9) was evaluated using flow cytometry and fluorescence
microscopy [20]. Briefly, for flow cytometric analysis, cou-
marin 6-labelled NCs were suspended in Optimem® media
and added to CT26 cells for 24 h in 6-well plates. Cells were
collected by trypsinisation and treated with FACS buffer.
Cellular uptake of SL-loaded NC was quantified by gating
cells for positive coumarin 6 fluorescence for CT26 control
cells (untreated) and cells treated with either free coumarin 6
or coumarin 6-labelled NC in the FITC channel detector (BD
FACS Calibur flow cytometer, BD Biosciences). The mea-
surements were performed in triplicate.
Cellular localisation of coumarin 6-tagged SL-loaded NC
was evaluated qualitatively by fluorescence microscopy
(Olympus DP-71, Olympus, Center Valley, PA, USA).
Intracellular distribution of fluorescent NC into CT26 cells
was detected using fluorescence imaging 1 day after treat-
ment. CT26 cells were seeded into a 6-well plate, containing
two fixed coverslips incubated into 2.0 ml of RPMI growth
medium. Coverslips were mounted using mounting media
(VectaShield) and subsequently counterstained with DAPI.
Cellular localisation of labelled NC was represented by the
green signals, while cells nuclei were detected in blue. The
untreated CT26 cells and cells treated with free coumarin 6
were used as negative and positive controls, respectively.
In vitro cell viability assay
CT26 murine colon cancer cells and CCD-841-CoN normal
colon epithelium cells were seeded in 24-well plates and in-
cubated with 0.5 ml of complete growth media. After 24 h,
cells were treated with blank NC or three different concentra-
tions of SL (20, 40 and 60 μM) in either the free form or the
equivalent amount of SL-loaded NC (F9). Cytotoxicity was
examined using a modified MTT assay [26]. After treatment
for 24 h, the media were removed and 500 μl of MTTsolution
(15% v/v) was added to the cells. They were incubated for 3 h
at 37 °C and 5% CO2. DMSO (500 μl) was added, and the
absorbance at 570 nm was recorded (FLUO Star Omega mi-
croplate reader, BMG Labtech). Results were expressed as the
percentage cell viability, compared to controls. Each treatment
was tested three times and the measurements were presented
as an average ± SD (n = 3).
In vivo studies
Female Balb/c mice, weighing approximately 20 g and aged
between 4 and 6 weeks, were allowed to acclimatise to labo-
ratory conditions for 10 days before starting the experiment.
Mice were fed water and standard pellet chow ad libitum for
the duration of the in vivo experiment. All animal experiments
were performed in compliance with the UK Home Office
(1989) Code of Practice for the Housing and Care of
Animals used in Scientific Procedures. A xenograft model of
CT26 colon carcinoma was induced by implanting 1 × 106
cells in 0.1 ml PBS subcutaneously at both lower flanks
[12]. A palpable solid tumour mass developed 2 weeks fol-
lowing subcutaneous inoculation. All mice rendered tumour-
bearing were included in this study. The treatment protocol
was started on day 14 and extended to day 30 post-
implantation.
Three different groups (n = 4) were used in an organ
biodistribution study. Control animals in the first group were
injected with PBS. The second group was treated with F3 and
the third group was treated with F9 through IV injection. The
treated groups were injected intravenously with prepared DiR-
labelled SL-loaded NC in PBS solution at a dose of 10 mg SL
kg−1 and scanned using an in vivo imaging system (IVIS
Lumina Series III, Caliper Life Sciences, Perkin Elmer,
USA) at 1-, 4- and 24-h post-injection [12]. All animals were
kept anaesthetised with 1.5% isoflurane/98.5% oxygen to
maintain sedation during the scanning process. Ex vivo imag-
ing for excised major organs (heart, lung, liver, spleen, kidney
and tumours) was carried out immediately after full in vivo
scan. Fluorescence images were obtained using a DiR filter
with an exposure time of 1 s. All images were captured using
sequential acquisition spectra under un-mixing mode. The
collected fluorescence emission signals were measured as
mean fluorescence intensity.
Four groups (n = 6) were used in an in vivo antitumour
activity study. Once anaesthetised, subjects were injected via
the tail vein with the following:
(Group 1) 200 μL of saline (control group);
(Group 2) 200 μL of blank NC nano-suspension;
(Group 3) 200 μL free SL at a dose of 10 mg kg−1;
(Group 4) 200 μL of SL-loaded NC (F9) nano-
suspension containing SL at a dose of 10 mg kg−1.
All treatments were injected every 3 days with a total of 5
injections during the whole experiment period. Tumour vol-
umeswere recorded at the beginning of the treatment at day 14
post-implantation and every 2 days, thereafter, until the end of
the experiment. A digital calliper was used to record dimen-
sions (mm) and the whole tumour volume was recorded. Mice
were sacrificed after the end of the experiment by cervical
dislocation, and the tumour was excised and washed with
saline to measure its final mass.
Statistical analysis
For all in vitro experiments, data were presented as mean ±
SD. In in vivo experiment, results were presented as mean ±
SEM. Significant differences between different groups were
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examined using one-way ANOVA followed by post hoc
Tukey’s test. p < 0.05 was considered statistically significant
in all experiments.
Results and discussion
Polymeric SL-loaded NCs were fabricated using the
nanoprecipitation method, and the impact of formulation var-
iables, such as PEG density on the PLGA chain and the type
of oil core, on the physicochemical characteristics of the SL-
loaded NCs was investigated. Mean particle size, PDI, zeta
potential, encapsulation efficiency, in vitro release profile and
in vitro stability were determined. The aim of the work was to
use this data and select an optimised formulation for further
in vivo evaluation. This optimised formulation was consid-
ered to be one with the smallest diameter, best encapsulation
efficiency, longest shelf-life stability and controlled therapeu-
tic action.
Effect of polymer type on physicochemical properties
Modification of PLGA by incorporation of PEG blocks within
the polymeric structure is a common experimental variable
within the formulation strategy of a nanoparticulate system.
Effects on aqueous solubility of poorly soluble payloads, ag-
gregation, stability and opsonisation are often reported [12,
23]. However, the approach is also associated with further
advantages, such as improvement in antitumour efficiency
and targeting characteristics [19, 20]. Therefore, the physico-
chemical properties of different SL-loaded NC (F3, F6 and
F9) fabricated from three different PLGA polymers were in-
vestigated (Fig. 1). PLGA-based NC (F3) (196.5 ± 20.9 nm)
were significantly larger in size (p < 0.01) than NC prepared
from 10% PEGylated polymers of (F9) (117.5 ± 11.5 nm). A
non-significant difference was observed when compared to
5% PEGylated NC (F6) (177.4 ± 14.5 nm) (p ˃ 0.05). SL-
loaded NC prepared from 10% PEG-PLGA diblock copoly-
mers (F9) were significantly smaller than NC prepared from
5% PEG-PLGA copolymer (p < 0.01), (Fig. 1a). Similar re-
sults were observed during the preparation of polymeric nano-
spheres using the same polymers [22, 23]. This was attributed
to the effect of linked PEG molecules on the assembly of
smaller NC. Modification of PLGA backbone by addition of
PEG as a hydrophilic polar segment can affect the physico-
chemical properties of the SL-loaded NCs prepared from
PEGylated copolymers. The particle size is often increased
by an increase in the hydrophobic segment of the used copol-
ymer. Higher PEG content resulted in a smaller NP size, at-
tributable to the short chain length of 10% PEG-PLGA copol-
ymer compared to 5% PEG-PLGA and PLGA [23, 27]. All
SL-loaded NC showed low polydispersity index ranging from
0.19 to 0.38. Increasing the PEG content in the NC polymeric
coat resulted in a significant increase in PDI values compared
to PLGA NC (p < 0.05).
The ζ-potential of NC colloidal suspension plays an impor-
tant role in maintaining in vitro stability. In vitro stability of
colloidal suspension depends on the degree of electrostatic
repulsion between nanoparticles. Higher negative or positive
zeta potential values resulted in good in vitro stability with
low tendency of particles aggregation [26]. F3 exhibited
higher negative ζ-potential values (− 21.9 ± 2.8 mV) com-
pared to the PEGylated PLGA NC (F6 and F9) (p < 0.001)
(Fig. 1b). Increasing the PEG content in the backbone of the
polymeric coat from 5 to 10% had a non-significant effect on
the ζ-potential (p ˃ 0.05). The lower negative ζ-potential of
PEGylated NC is due to the presence of surface-decorated
PEG chains which mask the free negative surface charge rep-
resented by the free anionic groups of PLGA [22, 23].
The presence of PEG blocks in the copolymer structure
resulted in a significant increase in SL entrapment (p
< 0.001). Encapsulation efficiency was increased from 68.8
± 6 in PLGA to 92.18% ± 1.8% in 10% PEG-PLGA (Fig. 1c).
This can be explained by the amphiphilic nature of both the
polymer itself and SL. PEG regions of the copolymer will
most likely orientate towards the continuous aqueous phase,
which can associate with the hydrophilic regions of the SL
molecule. The hydrophobic part of the SL molecule will ori-
entate towards the oil core. Therefore, the PEG-PLGA diblock
copolymer creates a suitable microenvironment created by its
amphiphilic nature, leading to high SL loading [28].
The in vitro release profile showed comparable burst re-
lease of SL from the three different polymers (p ˃ 0.05). Burst
release after 24 h was 53.2% ± 8.9, 60% ± 4.2 and 50% ± 8.3
from F3, F6 and F9, respectively (Fig. 1d). The observed burst
release can be attributed to the high amount of SL attached to
the surface of PLGA and PEGylated due to its amphiphilic
nature and surface-active properties. Release of SL from
PLGA NC (F3) was sustained after the first 24 h, and release
became slower, with approximately 70% of SL released over
the experimental period of 72 h. The PEGylated PLGA NC
showed the faster release of SL after the first 24 h with ap-
proximately 90% and 97% of SL released over 72 h from F6
and F9, respectively.
Effect of oil core type
SL was poorly soluble in palm oil (1.06 mg ml−1), being
s igni f icant ly lower than that in both cas tor oi l
(1.79 mg ml−1) and glyceryl monocaprate (2.21 mg ml−1).
The physicochemical characteristics of different SL-loaded
NC fabricated using these different oil cores are shown in
Fig. 2. SL-loaded NC based on glyceryl monocaprate (F9)
exhibited significantly lower size (117.5 ± 11.5 nm) compared
to NC-palm oil (F8) (162.5 ± 17.2 nm) and NC-castor oil (F7)
(179.2 ± 13.1 nm) for the 10% PEGylated copolymer types (p
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< 0.05). However, this trend was not apparent in the PLGA
NC (Fig. 2a). Type of oily core had a significant impact on the
physicochemical properties of SL-loaded NCs. At room tem-
perature, vegetable oils such as palm oil and castor oil showed
higher viscosity relative to glyceryl monocaprate. The smaller
size (p < 0.05) observed for (F9) is probably a consequence of
the lower viscosity of the glyceryl monocaprate compared
with the palm oil and castor oil used for preparation of F8
and F7, respectively [29]. The PDI values (data not shown)
for glyceryl monocaprate cores were significantly lower than
the palm oil and castor oil formulations. Variation in oil type
did not have any significant effect on the ζ-potential of the
different NC formulations (p ˃ 0.05) (Fig. 2b).
The % encapsulation efficiency of all SL-loaded NC
ranged from 56.3 ± 5.9 to 92.18% ± 1.8%. Glyceryl
monocaprate-based NC exhibited the highest encapsulation
efficiency values compared to other oil-based formulation,
regardless the type of the polymer (Fig. 2c). This is attributed
to solubility of SL in glyceryl monocaprate, which prevented
its undesirable loss towards the aqueous phase leading to a
high degree of entrapment. In addition, glyceryl monocaprate
has a lower hydrophilic–l ipophilic balance (HLB
approximately 5–6) than castor oil (HLB 14) and palm oil
(HLB 10). Therefore, NC based on a glyceryl monocaprate
core may offer a favourable microenvironment for encapsu-
lating water-insoluble glycolipids, such as lactonic SL [30].
This finding has been demonstrated in other work, where the
highest encapsulation efficiency of paclitaxel was observed in
glyceryl monocaprate nanocapsule cores compared with that
in other oils (palm oil and coconut oil) [31]. Similar findings
are observed for entrapment of curcumin into castor oil-based
nanocapsule due to enhanced solubility in the core medium
[12].
In vitro release profiles showed that changing the oil core
influenced the initial burst release from different NC (Fig. 2d).
In PLGA-based NC, a higher burst release had been observed
from F3 (containing glyceryl monocaprate) compared to F1
and F2 containing castor oil or palm oil, respectively. The
opposite effect was then observed for PEGylated NC under
the same conditions. The initial burst release after 24 h was
less for glyceryl monocaprate compared to other oils. This
might be attributed to a polymer-oil interaction driven by the
relative hydrophilicity of the polymer. The higher burst release
for PLGA NC might be due to its favourable association with
Fig. 1 Effects of polymer type on NC size (a), zeta potential (b), encapsulation efficiency (c) and SL in vitro release (d). Values are mean ± SD with
n = 3. For 1a–c, p < 0.05, **p < 0.01, ***p< 0.001 compared with PLGA (F3). Δp < 0.05, ΔΔp < 0.01 compared with 5% PEG-PLGA (F6)
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glyceryl monocaprate, which led to longer solidification time
and, consequently, to the formation of more porous NC struc-
ture, facilitating drug release [20].
Fig. 2 Effects of the oil core type on NC size (a), zeta potential (b),
encapsulation efficiency (c) and in vitro SL release (d). Values are
mean ± SD with n = 3. For 2a–c, *p < 0.05, **p < 0.01, p < 0.001
compared with castor oil for each polymer type. Δp < 0.05, p < 0.01,
ΔΔΔp < 0.001 compared with palm oil for each polymer type
Fig. 3 TEM images of SL-loaded NC (F9) after formulation







F3 0 196.5 ± 20.9 0.19 ± 0.03 − 21.9 ± 2.8
10 205.3 ± 18.7 0.18 ± 0.04 − 19.5 ± 2.5
20 217.7 ± 21.5 0.22 ± 0.05 − 18.7 ± 3.9
30 226.4 ± 15.3 0.25 ± 0.03 − 19.8 ± 3.4
F6 0 177.4 ± 14.5 0.26 ± 0.02 − 9.1 ± 1.01
10 191.5 ± 11.9 0.29 ± 0.05 − 10.2 ± 2.1
20 209.3 ± 16.8 0.28 ± 0.04 − 8.9 ± 2.4
30 217.3 ± 19.5 0.35 ± 0.03 − 7.9 ± 1.6
F9 0 117.5 ± 11.5 0.29 ± 0.04 − 8.2 ± 0.97
10 126.7 ± 13.6 0.3 ± 0.07 − 7.7 ± 1.2
20 135.3 ± 15.8 0.33 ± 0.03 − 8.1 ± 2.4
30 143.3 ± 12.2 0.35 ± 0.04 − 7.8 ± 1.9
Results are presented as mean ± SD with n = 3
*p ˂ 0.05 compared to day 0 for the same formula
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Transmission electron microscopy
The appropriate morphology of nanoparticulate drug delivery
system is crucial for the successful design of therapeutic drug
delivery systems. In this work, TEM was used to visualise the
particulate and to evaluate aggregation or adhesion of SL-
loaded NC. TEM images revealed a smooth spherical shape
of (F9) homogenous size with no aggregations (Fig. 3). The
average size obtained from TEM was comparable to what
obtained by light scattering.
Fig. 5 Fluorescence microscope
images of control cells (a–c), cells
treated with coumarin 6 (d–f) and
coumarin 6 tagged SL-loaded NP
(F9) (g–i) after 24 h of treatment
Fig. 4 Quantitative cellular
uptake of different types of SL-
loaded NC after 24 h, as deter-
mined by flow cytometry.
Individual histograms
representing fluorescence shift
resulted after treatment with F3
(a), F6 (b) and F9 (c). Direct
comparison of percentage of pos-
itive cells showing cellular uptake
of each NC (d). Values are mean
± SD with n = 3. For 4d ***p
< 0.001 compared with control
and coumarin 6 groups. ΔΔΔp
< 0.001 compared with F3 and F6
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In vitro stability of SL-loaded NC
After formulation of all SL-loaded NC, non-entrapped
drug was removed by gel filtration chromatography. The
purified NC formulations (F3, F6 and F9) were selected
for further study as they showed superior physicochemical
properties for each polymer type compared to other NC.
These formulations were characterised for their size, PDI,
ζ-potential immediately after purification at time zero and
every 10 days over 1 month of storage at 4 °C (Table 2).
The results from assessment of stability parameters, such
as time-dependent variation in particle size, confirmed
that F3 and F9 were sufficiently stable for 1 month after
preparation. There was a non-significant (p ˃ 0.05) in-
crease of size, PDI and zeta potential compared to freshly
prepared ones. Although F6 prepared from 5% PEG-
PLGA diblock copolymer showed non-significant
(p ˃ 0.05) increase in size and zeta potential, it showed
a significant (p ˂ 0.05) increase in PDI value after 30 days
from preparation. No apparent change in colour, clarity or
phase separation was observed in any of NC preparations.
Herein, stability results showed that SL-loaded NCs
prepared from 10% PEG-PLGA copolymer were biocom-
patible, stable and monodisperse nanosystem for SL en-
capsulation, with potential applications for drug delivery.
Our results prove that nanoprecipitation technique leads to
efficient stabilisation of oily core PEGylated NCs. The
in vitro stability measurements showed sufficient colloidal
stability for 1 month. Stability results confirmed lack of
evident destabilisation phenomena associated with no
degradation over time which can affect the size, PDI and
zeta potential of the prepared NCs.
Cellular uptake of SL-loaded NC
This study investigated the efficiency of cellular uptake of
SL-loaded PLGA and PEGylated PLGA NC by CT26
colon cancer cells. The effect of polymer type on the
in vitro cellular uptake results are shown in Figs. 4 and
5. The quantitative flow cytometry analysis was used to
detect the uptake of the coumarin 6-tagged SL-loaded NC
(F3, F6 and F9) in CT26 colon cancer cells after 24 h of
treatment (Fig. 4a–d). The intracellular uptake of fluores-
cent NC into CT26 cells was expressed by a fluorescence
shift from control cells depending on the fluorescence
intensity (Fig. 4a–c). The extent of cellular uptake was
measured secondly by the percentage of cells with posi-
tive staining following treatment (Fig. 4d). After 24 h, F9
exhibited significantly higher cellular uptake (p < 0.001)
than other NC formulations with lesser amounts of PEG
in the polymer coat (F3 and F6). Interestingly, these re-
sults were in good agreement with the optimum physio-
chemical properties of F9, with the lowest particle size,
highest PEG content and lowest zeta potential [20]. These
parameters gave rise to the greatest uptake in CT26 cells.
Previous results supported the higher cellular uptake of
PEGylated PLGA NC in CT26 cells, due to PEG pro-
nounced effect on decreasing nanoparticles size and
minimising the electrostatic repulsion force with the cell
membrane [12].
Given that SL and the other formulation components pos-
sess no fluorescent activity, it was necessary to add a fluores-
cent dye to determine the position of NC following exposure
in the test cell lines. Images from fluorescence microscopy
supported particulate uptake in CT26 cells (Fig. 5). The SL-
loaded NC (F9) were primarily localised in the cytoplasm,
while some fluorescence intensity was observed around the
nucleus, which supports possible intracellular localisation of
NC (Fig. 5g–i). Cells treated with coumarin 6 solution showed
minimal uptake as the dye was localised at the outer cell sur-
face (Fig. 5d–f). Based on these quantitative and qualitative
cellular uptake results, it can be concluded that SL-loaded
10% PEGylated PLGA NC (F9) showed maximum intracel-
lular uptake.
Fig. 6 CT26 cell viability results of different doses of free SL and SL-
loaded NC (F9) after 24, 48 and 72 h (a). CCD-841-CoN cell viability
results of different doses of free SL and SL-loaded NC (F9) after 24, 48
and 72 h (b). Values are expressed as mean ± SD with n = 3
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In vitro cytotoxicity
An assessment of the physicochemical data for all formula-
tions used in this work allowed selection of F9 as an optimised
formulation. This was based on F9 having the smallest size,
highest %EE, optimum shelf-life stability and highest cellular
uptake. Therefore, F9 was selected for further cell viability
and organ distribution studies.
The cytotoxic action of SL-loaded NC (F9) on CT26 colon
cancer cells and CCD-841-CoN normal colon epithelial cells
was evaluated byMTTassay after 24, 48 and 72 h of treatment
with 20, 40 and 60μMof free SL and SL-loadedNC (Fig. 6a).
Blank NC had no cytotoxicity action on colon cancer cells.
The dose-response curves were generated to detect the IC50
which is the drug concentration resulting in 50% growth inhi-
bition of colon cancer cells. Free SL showed a dose-dependent
effect as cell viability decreased with increasing dose from 20
to 60 μM. Significant reduction in cell viability compared to
control (p < 0.05) was observed. Treatment with SL-loaded
NC (F9) reduced cell viability in a dose-dependent effect
meanwhile it maintained its cytotoxic action up to 3 days after
treatment due to sustained drug release. The mean IC50 value
for SL-loaded NC (F9) in CT26 cells was approximately
60 μM, which was achieved within 24 h. Different doses of
free SL showed a slight decrease in cell viability of CCD-841-
CoN normal colon epithelial cells especially after 3 days of
treatment (Fig. 6b). Twenty-five percent reduction of cell via-
bility was observed after treatment with the highest dose of
60μMof free SL after 72 h. On the other hand, SL-loaded NC
(F9) achieved non-significant (p ˃ 0.05) cytotoxic effect on
normal colon epithelial cells within the concentration range
used in this study. This confirms the safety profile of the de-
signed drug delivery system compared to free drug for further
in vivo applications. Interestingly, these results are different
from other studies [10]. This might be due to the variation of
purity of SL used, due to different sources also due to the
lower range of drug concentration used in this study. These
results showed that NC drug delivery system can deliver SL to
its subcellular site and protect it from possible degradation to
achieve lower cell viability and greater cytotoxicity when
compared to the free SL after 24, 48, and 72 h of treatment
(p < 0.001).
Fig. 7 In vivo organ
biodistribution of DiR-labelled
SL-loaded NC (F3 and F9) in
CT26 tumour-bearing Balb/c
mice after i.v. injection.
Representative whole body
in vivo images obtained at 1, 4
and 24-h post-injection. All im-
ages were obtained by in vivo
imaging system (IVIS Lumina
III). Acquired data were analysed
by Living Image 4.3.1 Service
Pack 2 software
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In vivo tumour uptake and organ biodistribution
study
Tumour accumulation and organ biodistribution of DiR-
tagged SL-loaded NC (F3 and F9) were assessed in vivo in
mice bearing the murine colon cancer CT26 model. Whole-
body in vivo imaging was performed at 1, 4 and 24 h after
injection (Fig. 7). Imaging of excised organs, such as the heart,
lung, liver, spleen, kidneys and the tumour mass is shown in
Fig. 8.
In vivo imaging data from mice treated with PBS (control
group) confirmed that no background fluorescence was pres-
ent (data not shown). SL-loaded NC (F3) formulated from
PLGA polymer showed no tumour uptake after 1, 4 and
24 h, but did confirm accumulation in the liver and spleen
(Fig. 7). Tumour uptake of 10% PEGylated NC (F9) was
observed in both implanted tumours when imaged from the
dorsal and ventral view.
The excised organs from control animals (treated with
PBS) showed no fluorescence. Animal treated with F3
showed high fluorescence from both liver and spleen,
but low fluorescence from the tumour masses. Excised
organs from animals treated with F9 showed the highest
fluorescence intensities from the tumours when compared
to other organs (Fig. 8a). Fluorescence intensities from
each organ were further quantified (Fig. 8b) showing
mean fluorescence intensities from tumours treated with
F9 to be highly significant compared to animals treated
with F3 (p < 0.001) which confirms high tumour accumu-
lation of F9. Fluorescence intensity quantified from the
liver in animals treated with F3 was highly significant
compared to animals treated with F9 (p < 0.001).
Size and surface properties of nanocarriers play an impor-
tant role in controlling drug pharmacokinetics, biodistribution
and drug resistance in some cancer cells [32, 33].
Nanoparticles ≥ 200 nm and without surface modification will
induce the host immune systems to be engulfed by hepatic
Kupffer cells and other reticuloendothelial cells, resulting in
their rapid clearance from the circulation system.
Nanoparticles with size ≤ 150 nm and PEG modification
Fig. 8 Ex vivo organ
biodistribution of DiR-labelled
SL-loaded NC (F3 and F9) in
CT26 tumour-bearing Balb/c
mice after IV injection.
Representative ex vivo images of
excised organs after 24 h of in-
jection (a). All images were ob-
tained by IVIS Lumina III.
Acquired data were analysed by
Living Image 4.3.1 Service Pack
2 software. Ex vivo quantification
of fluorescence signals of SL-
loaded NC (F3 and F9) per gram
of excised organs and tumours
after 24 h was represented (b).
Values are presented as mean ±
SD (n = 4), For 8b, *p < 0.05, p
< 0.01, ***p < 0.001 compared
with PLGA (F3)
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appear to be appropriate for passive targeting as they are better
able to exploit site-specific endothelial irregularities and his-
tological variability [28, 34, 35]. An appreciation of this often-
debated EPR effect in solid tumours is one of the essential
prerequisites for designing a successful antitumour drug de-
livery. As shown in this study, F9 fulfils the requirements for a
long-circulating NC as its size (117.5 ± 11.5 nm) and PE-
decorated surface are considered to be desirable features. F9
is, therefore, optimum for passive targeting to colon cancer
due to its preferable biodistribution, which will lead to the
highest therapeutic efficacy in vivo.
In vivo antitumour activity
A low number of studies have investigated the therapeutic
potential of SL in vivo. A sepsis model has been used, which
Fig. 9 Tumour volume recorded
for the studied animal groups
every 2 days from the 1st day of
the treatment to the last record at
the 16th day (the end of the
experiment). Values are mean ±
SEM with n = 6. *p< 0.05, **p
< 0.01, ***p < 0.001 compared
with control group. Δp < 0.05,
ΔΔp < 0.01, ΔΔΔp < 0.001
compared with animal treated by
free SL at a dose of (10 mg kg−1)
(a). Percentage tumour growth
inhibition (% TGI) in animals
treated with free SL or SL-loaded
NC (F9) at a dose of (10 mg kg−1)
Δp < 0.05, ΔΔp < 0.01,
ΔΔΔp < 0.001 compared with an-
imal treated by free SL (b).
Tumour weight of studied groups
after the end of the experiment.
Values are mean ± SEM with
n = 6. p < 0.05, **p < 0.01, ***p
< 0.001 compared with control
group. Δp < 0.05, ΔΔp < 0.01,
ΔΔΔp < 0.001 compared with
animals treated by free SL at a
dose of (10 mg kg−1) (c)
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showed that SL mixtures containing both acidic and lactonic
SL reduced mortality in rats with experimentally induced sep-
sis via cecum puncture [36]. Recently, in vivo anticancer
models have been used to study the anticancer activity of SL
against human cervical cancer [11].
All animal involved in this study appeared healthy through-
out the whole experiment duration and no significant
(p ˃ 0.05) loss in body weight was detected. There were no
toxicity signs after treatment with either free SL or SL-loaded
NC (F9) at the drug concentration used. The dose used for this
study was 10 mg SL per kg of mice weight, and 5 injections
were administrated in vivo to the mice. The in vivo tumour
growth inhibition study in mice bearing CT26 colon cancer
after SL treatment showed no antitumour activity of blank NC
and a pronounced anticancer effect of SL-loaded NC (F9)
(Fig. 9a). The average tumour size of animals treated with
F9 was significantly lower compared to the control group
and animals treated with the free drug (p < 0.001). At the
end of the experiment, the average size of the tumour mass
of control animals treated with saline was found to be 993.5 ±
142.5 mm3. The average tumour size of animals treated with
free SL was 706.7 ± 105.3 mm3 and the percentage tumour
growth inhibition (% TGI) was 28.9%. A more pronounced
effect was recorded in animals treated with F9. There was a
significant reduction in the volume of tumour mass at each
time point starting from the 10th day till the end of the exper-
iment when compared with control and free drug-treated
group. The final average size of tumour was found to be de-
creased to 426.6 ± 115.4 mm3 and the % TGI was 57.09%
(Fig. 9b). It was observed that the F9 achieved a significant
reduction in tumour size (p < 0.001) confirming its greater
antitumour activity than free SL.
At the end of the in vivo experiment, all mice were
sacrificed, and implanted tumours were excised and weighed
(Fig. 9c). The change in tumour weights was observed in the
case of animals treated with free SL or F9. Treatment of mice
with F9 reduced the average tumour weight to 0.62 ± 0.1 g
compared to 1.6 ± 0.46 g for control animals with a percentage
reduction of 61.25%, which is highly significant compared to
control (p < 0.001) and free drug-treated mice (p < 0.01). The
percentage reduction in tumour weights was 37.5% in mice
treated with free SL, which is statically significant compared
to control mice (p < 0.01).
Conclusions
This study investigated, for the first time, the formulation and
optimisation of a nanocapsule drug delivery system for SL
encapsulation and in vivo administration in CT26 colon can-
cer. Formulation of PEG-PLGA-based polymeric NC with an
oil core showed high SL loading and sub-micrometre particle
size. PEGylated 10% NC (F9) showed superior physio-
chemical properties compared to similar SL-loaded PLGA
NC and a favourable shelf-life stability. This formulation
achieved efficient cellular uptake by CT26 colon cancer cell
line compared to other polymeric NC which facilitated its
cytotoxic action in vitro meanwhile it was safe to normal
colon cells. PEGylation makes F9 suitable for passive
targeting due to a prolonged blood circulation profile by evad-
ing the immune system thus maximising its accumulation in
colon tumour mass and minimising its unnecessary
biodistribution to other body organs after i.v. administration.
F9 was capable of inhibition of tumour growth and tumour
weight in vivo while being safe to treated subjects. In conclu-
sion, these results suggest that SL-loaded 10% PEGylated NC
could be an effective anticancer therapy for colon cancer. Our
future work will involve testing the anticancer activity of this
novel drug delivery system against different types of tumours.
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